Chronometric Administration of Cyclophosphamide and a Double-Stranded DNA-Mix at Interstrand Crosslinks Repair Timing, Called “Karanahan” Therapy, Is Highly Efficient in a Weakly Immunogenic Lewis Carcinoma Model

Vera Ruzanova, Anastasia Proskurina, Yaroslav Efremov, Svetlana Kirikovich, Genrikh Ritter, Evgenii Levites, Evgenia Dolgova, Ekaterina Potter, Oksana Babaeva, Sergey Sidorov, Oleg Taranov, Alexandr Ostanin, Elena Chernykh, Sergey Bogachev

Research output: Contribution to journalArticlepeer-review

Abstract

Background and Aims: A new technology based on the chronometric administration of cyclophosphamide and complex composite double-stranded DNA-based compound, which is scheduled in strict dependence on interstrand crosslinks repair timing, and named “Karanahan”, has been developed. Being applied, this technology results in the eradication of tumor-initiating stem cells and full-scale apoptosis of committed tumor cells. In the present study, the efficacy of this novel approach has been estimated in the model of Lewis carcinoma. Methods: To determine the basic indicative parameters for the approach, the duration of DNA repair in tumor cells, as well as their distribution along the cell cycle, have been assessed. Injections were done into one or both tumors in femoral region of the engrafted mice in accordance with the developed regimen. Four series of experiments were carried out at different periods of time. The content of poorly differentiated CD34+/TAMRA+ cells in the bone marrow and peripheral blood has been determined. Immunostaining followed by the flow cytometry was used to analyze the subpopulations of immune cells. Results: The high antitumor efficacy of the new technology against the developed experimental Lewis carcinoma was shown. It was found that the therapy efficacy depended on the number of tumor growth sites, seasonal and annual peculiarities. In some experiments, a long-term remission has been reached in 70% of animals with a single tumor and in 60% with two tumors. In mice with two developed grafts, mobilization capabilities of both poorly differentiated hematopoietic cells of the host and tumor stem-like cells decrease significantly. Being applied, this new technology was shown to activate a specific immune response. There is an increase in the number of NK cell populations in the blood, tumor, and spleen, killer T cells and T helper cells in the tumor and spleen, CD11b+Ly-6C+ and CD11b+Ly-6G+ cells in the tumor. A population of mature dendritic cells is found in the tumor. Conclusion: The performed experiments indicate the efficacy of the Karanahan approach against incurable Lewis carcinoma. Thus, the discussed therapy is a new approach for treating experimental neoplasms, which has a potential as a personalized anti-tumor therapeutic approach in humans.

Original languageEnglish
Article number1610180
JournalPathology and Oncology Research
Volume28
DOIs
Publication statusPublished - 27 May 2022

Keywords

  • cancer stem cells
  • committed tumor cells
  • cytostatic agent
  • dsDNA
  • interstrand crosslink repair
  • Karanahan approach
  • Lewis lung carcinoma
  • tumor growth site
  • Antigens, CD34
  • Cyclophosphamide/pharmacology
  • Humans
  • Mice, Inbred C57BL
  • Neoplastic Stem Cells/pathology
  • DNA/genetics
  • Animals
  • Carcinoma/pathology
  • Mice

OECD FOS+WOS

  • 3.02 CLINICAL MEDICINE
  • 3.01 BASIC MEDICAL RESEARCH

Fingerprint

Dive into the research topics of 'Chronometric Administration of Cyclophosphamide and a Double-Stranded DNA-Mix at Interstrand Crosslinks Repair Timing, Called “Karanahan” Therapy, Is Highly Efficient in a Weakly Immunogenic Lewis Carcinoma Model'. Together they form a unique fingerprint.

Cite this